# Phase 1 Study for IPG11406 in Health Volunteer

> **NCT06255834** · PHASE1 · COMPLETED · sponsor: **Nanjing Immunophage Biotech Co., Ltd** · enrollment: 66 (actual)

## Conditions studied

- Inflammatory Bowel Diseases

## Interventions

- **DRUG:** IPG11406

## Key facts

- **NCT ID:** NCT06255834
- **Lead sponsor:** Nanjing Immunophage Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-24
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06255834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06255834, "Phase 1 Study for IPG11406 in Health Volunteer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06255834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*